The global phenomenon of glucagon-like peptide-1 receptor agonist medications has transformed the landscape of obesity medicine, and now it is reshaping the practice of plastic and reconstructive surgery as well. Millions of patients who have achieved substantial pharmacologic weight loss are increasingly presenting to surgeons for body contouring procedures to remove excess skin and reshape tissue after dramatic slimming. Against this backdrop, a recent systematic review and meta-analysis published in BMC Plastic and Reconstructive Surgery raised a clinically urgent question: do these popular medications, commonly known by brand names such as Ozempic and Wegovy, increase the risk of surgical wound complications? The original analysis by Collaco and colleagues reported a possible association between GLP-1 receptor agonist use and wound dehiscence, the splitting open of a surgical incision, a finding that immediately drew attention from surgeons and patients alike. But a new commentary from an international group of researchers argues that the story is considerably more nuanced, and that the dehiscence signal should be interpreted with careful methodological scrutiny rather than accepted at face value.
The commentary, authored by Syeda Bareera of Khyber Girls Medical College in Peshawar, Syed Hatim Hussain and Syed Muhammad Momin of Nowshera Medical College, Syed Muhammad Ahmad of Khyber Medical College, and Muhammad Fayyaz of Sphinghar University in Afghanistan, does not dismiss the original findings. Instead, the authors contend that the apparent link between GLP-1 receptor agonists and wound dehiscence may depend heavily on how drug exposure is defined, how rare outcomes are handled statistically, and whether wound risk is evaluated at the level of specific procedures rather than broad surgical categories. These three methodological distinctions, they argue, deserve far closer consideration before surgeons change practice or patients become alarmed. The commentary is a masterclass in the kind of critical appraisal that modern evidence-based medicine demands, particularly when a topic touches one of the most widely discussed drug classes in the world.
The first and perhaps most consequential point concerns the definition of exposure itself. The commentary authors emphasize that GLP-1 receptor agonist use should never be treated as a single, uniform perioperative exposure. There is a profound clinical difference between a patient who is actively taking a weekly injection in the days surrounding surgery, a patient who temporarily withheld the medication shortly before the operation, and a patient who discontinued therapy months earlier and has since achieved stable weight and nutritional status. Each of these scenarios carries a distinct physiological profile, and each could plausibly exert a different influence on wound healing. Yet in the studies included in the original meta-analysis, perioperative exposure timing was inconsistently reported at best. In some cohorts, cessation of the drug ranged from just one week before surgery to an average of 9.6 weeks, while in other cohorts the timing of discontinuation was not reported at all. This heterogeneity makes it genuinely difficult to know what the pooled estimates actually represent.
This ambiguity matters because clinical guidance on perioperative GLP-1 receptor agonist management has itself evolved rapidly. The initial recommendation from the American Society of Anesthesiologists advised holding weekly agents for one week before surgery, largely out of concern for residual gastric contents and aspiration risk during anesthesia. More recent multi-society guidance has shifted toward individualized assessment, weighing the timing of the last dose, the presence of gastrointestinal symptoms such as nausea and delayed gastric emptying, recent dose escalation, and patient-level risk factors. Against this moving target, the commentary authors argue that future studies must categorize exposure according to clinically meaningful perioperative windows: continued therapy, short-term withholding, prolonged withholding, or discontinuation after weight stabilization. They also suggest that investigators apply target trial emulation principles, a framework for causal inference from observational data championed by epidemiologist Miguel Hernán and colleagues, which aligns exposure assignment, follow-up, and outcome assessment with the causal question a randomized trial would ask. Only then, they contend, can observational analyses begin to disentangle the true effect of the drugs from the effects of weight change, nutrition, and timing.
The second methodological concern involves the statistical handling of rare events, a notoriously thorny problem in meta-analysis. In one of the included studies, led by Liang and colleagues, researchers reported zero surgical site infection events among GLP-1 receptor agonist users compared with seven events among controls, creating what statisticians call a single one-arm zero-event cell. Zero cells are poison for conventional risk ratio calculations, because dividing by zero is mathematically undefined and the choice of a continuity correction, a small artificial adjustment added to every cell, can materially change the pooled estimate. The original meta-analysis used Mantel-Haenszel random-effects risk ratios for binary outcomes, but the commentary authors note that it remains unclear whether a continuity correction was applied. They argue that a brief clarification of this analytic choice would help readers judge the robustness of the nonsignificant surgical site infection finding, and they cite the work of Xu and colleagues, who have proposed that meta-analysts select analytic methods according to the specific zero-event structure of their data rather than defaulting to a single approach.
Beyond clarification, the commentary authors recommend sensitivity analyses to test whether the nonsignificant infection finding survives alternative analytic conventions. These could include the Mantel-Haenszel risk difference, appropriate one-stage models, or Peto odds ratios, though the latter are only appropriate when groups are reasonably balanced and treatment effects are small. The point is not academic pedantry. When outcomes are uncommon and event counts are sparse, the apparent absence of a statistical signal can be an artifact of the analytic method rather than a genuine reflection of safety. For clinicians deciding whether to delay surgery or alter medication management, understanding the degree of uncertainty around nonsignificant findings is essential. The commentary authors argue that transparent reporting of these conventions would allow readers to interpret uncommon outcome estimates with appropriate caution, rather than mistaking statistical silence for evidence of no effect.
The third concern is arguably the most intuitive: the composite category of body contouring surgery may simply be too broad for an outcome as mechanically dependent as wound dehiscence. Panniculectomy, abdominoplasty, lipoabdominoplasty, brachioplasty, thighplasty, and mastopexy differ dramatically in incision length, flap tension, extent of undermining, dead space, drain use, and postoperative mechanical stress on the closure. High-tension abdominal procedures such as panniculectomy and abdominoplasty may involve broad dissection and challenging closure-tension dynamics, whereas mastopexy or brachioplasty involve entirely different anatomic sites, incision geometry, and postoperative forces. These factors are directly related to dehiscence risk and are not interchangeable across procedure types. Pooling them into a single body contouring category risks diluting or distorting any true procedure-specific signal, and the commentary authors argue that future work should stratify analyses by procedure type wherever sample size permits, particularly separating high-tension abdominal operations from other contouring procedures.
The commentary extends this procedural critique to the outcome definitions themselves. Surgical site occurrences, as commonly reported in the plastic surgery literature, combine events with fundamentally different mechanisms: infection, seroma, hematoma, and dehiscence. The Centers for Disease Control and Prevention’s National Healthcare Safety Network framework links surgical site infection surveillance to operative procedure category and tissue depth, while leading plastic surgery researchers such as Gabriel, Gupta, and Orgill have emphasized the clinical importance of distinguishing among these wound events rather than treating them as interchangeable. A pooled estimate that blends a seroma with a wound separation tells clinicians very little about either. The commentary authors call for predefined wound-event definitions, standardized follow-up intervals, and procedure-stratified analyses in future research, arguing that only this level of granularity will reveal which patients, which operations, and which perioperative management strategies genuinely warrant additional caution.
Crucially, the authors are careful to frame their critique as a call for cautious interpretation rather than a rejection of the original work. They acknowledge that the finding of a possible association between GLP-1 receptor agonist use and wound dehiscence is clinically important, particularly as plastic surgeons increasingly encounter patients arriving after pharmacologic weight loss, often with altered nutritional status, rapid changes in tissue quality, and complex medication histories. The current evidence, they write, is clinically valuable but limited by heterogeneity and variable reporting across the underlying primary studies. Their goal is to ensure that the dehiscence signal stimulates better-designed research rather than premature clinical dogma. In an era when a single headline about a blockbuster drug class can reshape patient behavior overnight, the distinction between a preliminary association and an established risk is not a technicality; it is the difference between informed decision-making and unnecessary alarm.
The broader lesson of this scholarly exchange extends well beyond GLP-1 receptor agonists and the operating room. It illustrates how the quality of a meta-analysis is ultimately bounded by the quality and granularity of the primary studies it pools, and how seemingly technical choices, the definition of an exposure window, the treatment of a zero cell, the boundaries of a surgical category, can shape conclusions that reach millions of patients. As the obesity medication revolution continues and the wave of post-weight-loss body contouring surgery swells, the surgical community now has both a warning and a roadmap: take the wound-healing question seriously, but answer it with the methodological rigor it demands. Patients contemplating surgery while on these medications should discuss timing and individual risk with their surgical and prescribing teams, guided by evolving multi-society recommendations rather than by any single pooled estimate.
Subject of Research: Perioperative safety of GLP-1 receptor agonists in body contouring surgery
Article Title: Comment on: Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis
Article References: Bareera, S., Hussain, S. H., Momin, S. M., Ahmad, S. M., & Fayyaz, M. (2026). Comment on: Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis. BMC Plastic and Reconstructive Surgery, 2(1), Article 20. https://doi.org/10.1186/s44452-026-00033-9
Image Credits: AI Generated
DOI: 10.1186/s44452-026-00033-9
Keywords: GLP-1 receptor agonists, body contouring surgery, wound dehiscence, meta-analysis, systematic review, surgical site infection, perioperative management, plastic surgery, weight loss medications, zero-event studies, surgical complications, target trial emulation
Cite Scienmag News
APA
MLA
Chicago
Ophelia Keating. (September 12, 2026). Weight-Loss Drugs and Wound Healing: New Warning for Body Contouring Surgery. Scienmag. https://scienmag.com/weight-loss-drugs-and-wound-healing-new-warning-for-body-contouring-surgery/
Ophelia Keating. “Weight-Loss Drugs and Wound Healing: New Warning for Body Contouring Surgery.” Scienmag, 12 September 2026, https://scienmag.com/weight-loss-drugs-and-wound-healing-new-warning-for-body-contouring-surgery/. Accessed 12 September 2026.
Ophelia Keating. “Weight-Loss Drugs and Wound Healing: New Warning for Body Contouring Surgery.” Scienmag. September 12, 2026. https://scienmag.com/weight-loss-drugs-and-wound-healing-new-warning-for-body-contouring-surgery/
Copy citation
Download RIS
Tags: body contouring after pharmacologic weight lossbody contouring surgerycomplications of body contouring proceduresGLP-1 receptor agonistsGLP-1 receptor agonists in obesity treatmentimpact of Ozempic and Wegovy on plastic surgery outcomesmeta-analysismethodological analysis of wound healing studiesobesity pharmacotherapy and reconstructiveperioperative managementplastic surgerysurgical complicationssurgical safety considerations with GLP-1 receptor agonistssurgical site infectionsystematic reviewsystematic review of weight-loss medication complicationstarget trial emulationWeight loss medicationsWeight-loss drugs and surgical wound healingwound dehiscencewound dehiscence risk factors in surgerywound healing challenges post-bariatric surgeryzero-event studies
